OPKO bags US’ No 3 clinical lab operator for $1.47bn
This article was originally published in Clinica
Executive Summary
OPKO Health has agreed to acquire Bio-Reference Laboratories (BRL), the third largest full-service clinical laboratory in the US with a strong focus on genetic testing, in an all-stock deal worth $1.47bn. The deal will provide Miami-based OPKO with an extensive US sales and distribution network through which it can commercialize its recently launched 4Kscore test, for predicting the risk of aggressive prostate cancer, and other diagnostics tests from OPKO’s pipeline.